Replies to post #514339 on NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

Clearly keep repeating the same bs lmao. The optune trial had over 50% with IDH1 mutation whereas DCVax had only 7 of 331. Completely skewed results in the optune trial.

Complete BS.

The Optune nGBM trial did not test all for IDH status. Of the few hundred it tested the mutant type was 7%.

That somebody found some write up someplace that had this number wrong does not matter. The actual paper (and even the NYAS slides from LL) list 7%.

[HyGro]

So NWBO SEC reported information, Dr. Liau's journal publication, NWBO press releases, FDA Guidance documents are B.S.?

Optune was approved for GBM, not mutations, etc. As DCVax-L has not been approved, doesn't seem to have any commercial organization, not going to be a SoC.
We'll see how this plays out but treatments don't become SoC without significant commercial support. NWBO has none.